Actinium Pharmaceuticals (ATNM) Receives a Buy from JonesTrading


In a report released today, Matthew Cross from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals (ATNM), with a price target of $4. The company’s shares opened today at $0.24, close to its 52-week low of $0.23.

Cross wrote:

“We have revised our estimates to reflect these timeline expectations, but remain firmly impressed with Iomab-B’s safety, feasibility, and early efficacy findings in SIERRA and optimistic about the trial’s odds of a positive conclusion. Having reached this key checkpoint, the next potential SIERRA- related catalyst is likely to be safety and feasibility data (akin to what was presented at ASH 2018 for the first 25% of patients in SIERRA) for the first 50% of patients now enrolled, which may be reported at ASH this December, if not sooner. Additionally, we hope to see confirmation of the standout effects of Iomab-B alone on pre-transplant blast counts among the 75 patients currently enrolled (potentially in 1H:20) as a follow-up to what was seen in the first 38 patients at ASCO last month. We maintain our BUY rating but lower our 12-month price target to $4.00/share from $4.75/share.”

According to TipRanks.com, Cross has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.4% and a 32.3% success rate. Cross covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Catalyst Biosciences Inc, and Aldeyra Therapeutics.

Currently, the analyst consensus on Actinium Pharmaceuticals is a Moderate Buy with an average price target of $3.13, implying a 1204.2% upside from current levels. In a report issued on July 9, Maxim Group also maintained a Buy rating on the stock with a $1.50 price target.

See today’s analyst top recommended stocks >>

Based on Actinium Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $5.67 million. In comparison, last year the company had a GAAP net loss of $4.86 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts